Do Microbes in the Gut Trigger Parkinson’s Disease?
In a PD mouse model, microbes pump out short-chain fatty acids that worsen synuclein aggregation and motor problems. Intestinal flora from people appears to do the same.
6404 RESULTS
Sort By:
In a PD mouse model, microbes pump out short-chain fatty acids that worsen synuclein aggregation and motor problems. Intestinal flora from people appears to do the same.
Researchers at SfN 2016 painted a more detailed picture of how misfolded proteins may proliferate, as one cell spreads these “hot potatoes” to the next.
Cell lines can serve as sensors for strains found in different human tauopathies.
Astrocytes and Exosomes Implicated in Protein Propagation Knock-In Alzheimer’s Mice Catch on More Broadly in the Field Next-Generation Mouse Models: Tau Knock-ins and Human Chimeras Inflammation Helps Microglia Clear Amyloid from AD Brains Exosomes and An
Researchers at SfN 2016 touted the advantages of APP knock-ins, but noted they are less useful than overexpression models for studying behavior.
At SfN 2016, researchers debuted new mouse models that may better represent human disease.
Where does TREM2-dependent microglial activity fit into the staging diagram of Alzheimer’s disease?
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
CTAD: Solanezumab Seen to Nudge AD Ever so Slightly Tau Inhibitor Fails Again—Subgroup Analysis Irks Clinicians at CTAD Much ‘Adu’ About a Little: Phase 1 Data Feeds the Buzz at CTAD Tau PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages Em
The tau aggregation inhibitor LMTM tanks in second Phase 3 trial for Alzheimer’s. The sponsor now plans to develop the “placebo.”
Scientists at SfN presented innovative ways to slow amyloid accumulation and preserve synapses.
Cognitively normal people who harbor plaques in their brains are more likely to report feelings of isolation.
Sanofi Genzyme will test a compound currently in development for Gaucher’s disease in Parkinson’s patients who carry a glucocerebrosidase (GBA) mutation.
Biogen and Genentech rolled out more data from their Phase 1b trials, renewing hope that amyloid removal will work and shoring up dosing for Phase 3.
At CTAD, tau PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.